Advertisement

ADVERTISEMENT

Metastatic-Breast-Cancer

Kevin Kalinsky, MD, Winship Cancer Institute
Videos
Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
06/13/2024
Kevin Kalinsky, MD
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares...
06/13/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Remains Superior to Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/07/2024
Allison Casey
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival...
06/07/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer
06/06/2024
Allison Casey
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from...
06/06/2024
Oncology
Conference Coverage
Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
06/06/2024
Allison Casey
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a...
06/06/2024
Oncology
Xichun Hu, MD, PhD
Conference Coverage
Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer
06/03/2024
Xichun Hu, MD, PhD
Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...
Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...
Xichun Hu, MD, PhD, Fudan...
06/03/2024
Oncology
Conference Coverage
Palbociclib Plus Exemestane and Ovarian Function Suppression for HR-Positive, HER2-Negative Breast Cancer
06/02/2024
Allison Casey
According to updated survival data from the phase 2 Young-PEARL study, palbociclib plus exemestane with ovarian function suppression prolonged progression-free survival but not overall survival among patients with HR-positive, HER2-negative...
According to updated survival data from the phase 2 Young-PEARL study, palbociclib plus exemestane with ovarian function suppression prolonged progression-free survival but not overall survival among patients with HR-positive, HER2-negative...
According to updated survival...
06/02/2024
Oncology
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021

Janelle Bradley

Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer
12/07/2021

Janelle Bradley

Janelle Bradley
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021

Janelle Bradley

Janelle Bradley
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer
12/06/2021

Janelle Bradley

Janelle Bradley
Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.
Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.
Medical oncologists reported...
12/06/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use